Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

BACKGROUND: Patient-reported outcomes (PROs) are increasingly relevant endpoints in clinical trials, contributing to our understanding of risk–benefit profiles, in addition to efficacy and safety data. We investigated the impact of entrectinib on patient-reported symptoms, functioning, and health-re...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:ESMO Open
Auteurs principaux: Paz-Ares, L., Barlesi, F., Siena, S., Ahn, M.-J., Drilon, A., Conley, A., Rolfo, C., Wolf, J., Seto, T., Doebele, R., Kapre, A., Chen, D., McCallum, S., Osborne, S., Demetri, G.
Format: Artigo
Langue:Inglês
Publié: Elsevier 2021
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100628/
https://ncbi.nlm.nih.gov/pubmed/33930659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100113
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires